E088 Investigating the impact of menopause and its treatment on women with systemic autoimmune rheumatic diseases: the Menopause MATTERs Mixed Methods Research Project
Notice bibliographique
Résumé
Abstract Background/Aims Menopause represents a significant and often overlooked transition in the lives of women, particularly those with systemic autoimmune rheumatic diseases (SARDs), such as lupus. Hormonal fluctuations during menopause may exacerbate SARDs symptoms, complicate disease management, and diminish quality of life (QoL). Despite these potential implications, the interaction between menopause and SARDs remains underexplored in clinical practice. This is particularly important for rheumatologists, who must navigate complex patient cases where hormonal shifts may directly influence disease activity and treatment outcomes. Understanding these dynamics could lead to more personalised care strategies that improve patient outcomes. Our exploratory work revealed that rheumatologists often lacked confidence in this aspect of care. A previous study suggesting that HRT may cause lupus to flare was cited by some rheumatologists as a reason for advising against HRT, yet patient and clinician experiences are rarely directly sought. The menopause MATTERs (Menopause And TreaTment Experiences in Rheumatic diseaseS) study aims to investigate the impact of menopause and its treatment on people with and without systemic autoimmune rheumatic diseases. Objectives 1. To understand and compare the impact of menopause on SARDs patients and healthy people. 2. To investigate the influence of hormone replacement therapy (HRT) on SARDs symptoms and QoL. 3. To assess the satisfaction with menopause-related advice, support, and treatment among SARDs patients and healthy people. Methods An exploratory mixed-methods approach will be employed across 3 workstreams: Workstream 1: Investigates and compares the physical and psychosocial impact of menopause on SARDs patients with healthy controls, using validated instruments including the menopause rating scale (MRS), depression (PHQ8) and anxiety (GAD-7) indexes, and qualitative interview data. Workstream 2: Examines the effect of HRT on SARDs symptoms and QoL using both quantitative measures (e.g., t-tests, linear regression) and qualitative analyses. Workstream 3: Summarises patient satisfaction with menopause advice and treatment using descriptive statistics and thematic analysis. Results The Menopause MATTERs survey will launch in November 2024. Surveys will be distributed online to SARD patients, the general population and clinicians. Anticipated minimum response rates based on our previous research are n = 1000 for SARD patients, n = 250 for clinicians, and n = 400 for the general population. Data analysis will commence in January 2025, incorporating both qualitative and quantitative methods to explore the effect of menopause and HRT on disease activity and QoL, and satisfaction with menopause-related advice. Conclusion We anticipate highly novel findings from this research which will provide essential insights to guide more nuanced, individualised care for women managing both menopause and chronic autoimmune diseases. A summary of findings from all workstreams will be presented at the conference. Disclosure K. Naidu: None. A. Kaul: None. Z. Mclaren: None. L. Andreoli: Consultancies; Consultancy fees from Eli Lilly, Glaxo Smith Kline, Janssen, Novartis, UCB, and Werfen Group. L. Holloway: None. S. Taylor: None. M. Piper: None. W. Diment: None. E. Dunbar: None. L. Gallagher: None. E. Trenah: None. F. Naughton: None. B. Sloan: None. T. Reilly: None. D. D’Cruz: Corporate appointments; A position on the APS charity leadership board. Consultancies; consultancy/speaker fees from GSK, Eli Lilly, Vifor and UCB. M. Sloan: None.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,042 | 0,031 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,001 | 0,004 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,003 | 0,001 |
| Communication savante | 0,002 | 0,002 |
| Science ouverte | 0,002 | 0,003 |
| Intégrité de la recherche | 0,002 | 0,002 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,023 | 0,003 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».